Literature DB >> 17408653

Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis.

Azza Karrar1, Ulrika Broomé, Towe Södergren, Marie Jaksch, Annika Bergquist, Mikael Björnstedt, Suchitra Sumitran-Holgersson.   

Abstract

BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is an autoimmune liver disease with destruction of hepatic bile ducts. A high frequency of biliary epithelial cell antibodies (BEC-Ab) is present in PSC. Here, we studied the mechanisms and signaling pathways used by these Ab in causing BEC dysfunction.
METHODS: Immunoassays were performed using freshly isolated BECs to study the signaling capacity of purified immunoglobulin (Ig) G and F(ab)'(2) fractions from 33 patients with PSC with anti-BEC-Ab.
RESULTS: We provide evidence that stimulation of BECs with PSC IgG, but not control IgG, induced expression of Toll-like receptor (TLR) 4 and TLR9 and specific phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 as well as the transcription factors ELK-1 and nuclear factor kappaB. A specific inhibitor of ERK1/2 abrogated phosphorylation of ELK-1 and protein expression of TLR4 but not TLR9 on BECs. TLR-expressing BECs, when further stimulated with lipopolysaccharide and CpG DNA, produced high levels of interleukin-1beta, interleukin-8, interferon gamma, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and transforming growth factor beta. Bile ducts stained positively for TLR4 and TLR9 in 58% of liver specimens taken from patients with PSC with BEC-Ab, as compared with 14% in those without BEC-Ab and also less frequently in diseased control livers.
CONCLUSIONS: Our data show that binding of PSC BEC-Ab initiates ERK1/2 signaling and up-regulation of TLR, which upon ligation induces BECs to produce cytokines/chemokines, leading to the possible recruitment of inflammatory cells. Thus, in PSC, BECs are not only targets of the immune attack but may also be active participants and mediators of their own destruction. BEC-Ab may be critical regulators of cholangitis in PSC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17408653     DOI: 10.1053/j.gastro.2007.01.039

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  51 in total

1.  Interferon regulatory factor 3 and type I interferons are protective in alcoholic liver injury in mice by way of crosstalk of parenchymal and myeloid cells.

Authors:  Jan Petrasek; Angela Dolganiuc; Timea Csak; Bharath Nath; Istvan Hritz; Karen Kodys; Donna Catalano; Evelyn Kurt-Jones; Pranoti Mandrekar; Gyongyi Szabo
Journal:  Hepatology       Date:  2011-01-10       Impact factor: 17.425

2.  Type I interferons protect from Toll-like receptor 9-associated liver injury and regulate IL-1 receptor antagonist in mice.

Authors:  Jan Petrasek; Angela Dolganiuc; Timea Csak; Evelyn A Kurt-Jones; Gyongyi Szabo
Journal:  Gastroenterology       Date:  2010-08-19       Impact factor: 22.682

3.  The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases.

Authors:  João-Bruno Soares; Pedro Pimentel-Nunes; Roberto Roncon-Albuquerque; Adelino Leite-Moreira
Journal:  Hepatol Int       Date:  2010-10-21       Impact factor: 6.047

4.  Cholangiocyte N-Ras protein mediates lipopolysaccharide-induced interleukin 6 secretion and proliferation.

Authors:  Steven P O'Hara; Patrick L Splinter; Christy E Trussoni; Gabriella B Gajdos; Pooja N Lineswala; Nicholas F LaRusso
Journal:  J Biol Chem       Date:  2011-07-13       Impact factor: 5.157

Review 5.  Autoantibodies in primary sclerosing cholangitis.

Authors:  Johannes-Roksund Hov; Kirsten-Muri Boberg; Tom-H Karlsen
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

Review 6.  The immunobiology of cholangiocytes.

Authors:  Xian-Ming Chen; Steven P O'Hara; Nicholas F LaRusso
Journal:  Immunol Cell Biol       Date:  2008-05-27       Impact factor: 5.126

7.  Xanthogranulomatous cholecystitis complicated with primary sclerosing cholangitis: report of a case.

Authors:  Akira Mori; Ryuichiro Doi; Yoshikuni Yonenaga; Shuichiro Nakabo; Shujiro Yazumi; Junya Nakaya; Fumihiko Kono; Toshiaki Manabe; Shinji Uemoto
Journal:  Surg Today       Date:  2010-07-30       Impact factor: 2.549

8.  Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis.

Authors:  Jinsheng Guo; Scott L Friedman
Journal:  Fibrogenesis Tissue Repair       Date:  2010-10-21

Review 9.  Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies.

Authors:  James H Tabibian; Steven P O'Hara; Keith D Lindor
Journal:  Scand J Gastroenterol       Date:  2014-07-03       Impact factor: 2.423

Review 10.  The immunobiology of primary sclerosing cholangitis.

Authors:  Jonathan H Aron; Christopher L Bowlus
Journal:  Semin Immunopathol       Date:  2009-05-26       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.